Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment

On 17 August 2020 the FDA announced the availability of the draft guidance for industry.

The purpose of this guidance is to assist sponsors in the clinical development of drugs and biological products for the treatment of acute myeloid leukemia (AML). Specifically, this guidance addresses FDA’s current thinking regarding the overall development program and clinical trial designs for the development of drugs to support an indication of treatment of AML, including indications limited to an individual phase of treatment (e.g., maintenance, transplantation preparative regimen, etc.).

Read more online 
Copyright Widler & Schiemann AG 2020. All Rights Reserved. /